NPM1 and myeloid neoplasm: Studies have validated that both FLT3-ITD and FLT3D835Y are driver mutations in AML that cause myeloid neoplasms in murine models [18, 19], FLT3-ITD occurs in about 25% of AML patients and represents an unfavorable prognosis unless nucleophosmin 1 (NPM1) mutations are present [20, 21].